Search

Your search keyword '"Dowdy, D. W."' showing total 113 results
Start Over Author "Dowdy, D. W."
Sorry, I don't understand your search. ×
113 results on '"Dowdy, D. W."'

1. Preference for daily (1HP) vs. weekly (3HP) isoniazid-rifapentine among people living with HIV in Uganda

Author

Musinguzi, A., primary, Aschmann, H. E., additional, Kadota, J. L., additional, Nakimuli, J., additional, Welishe, F., additional, Kakeeto, J., additional, Namale, C., additional, Akello, L., additional, Nakitende, A., additional, Berger, C., additional, Katamba, A., additional, Tumuhamye, J., additional, Kiwanuka, N., additional, Dowdy, D. W., additional, Cattamanchi, A., additional, and Semitala, F. C., additional

Published
2024
Full Text
View/download PDF

2. Cost to perform door-to-door universal sputum screening for TB in a high-burden community

Author

Baik, Y., Nakasolya, O., Isooba, D., Mukiibi, J., Kitonsa, P. J., Erisa, K. C., Nalutaaya, A., Robsky, K. O., Ferguson, O., Kendall, E. A., Sohn, H., Katamba, A., and Dowdy, D. W.

Subjects
Pulmonary and Respiratory Medicine, Infectious Diseases, Article
Abstract

BACKGROUND: Population-based active case-finding (ACF) identifies people with TB in communities but can be costly.METHODS: We conducted an empiric costing study within a door-to-door household ACF campaign in an urban community in Uganda, where all adults, regardless of symptoms, were screened by sputum Xpert Ultra testing. We used a combination of direct observation and self-reported logs to estimate staffing requirements. Study budgets were reviewed to collect costs of overheads, equipment, and consumables. Our primary outcome was the cost per person diagnosed with TB.RESULTS: Over a 28-week period, three teams of two people collected sputum from 11,341 adults, of whom 48 (0.4%) tested positive for TB. Screening 1,000 adults required 258 person-hours of effort at a cost of US$35,000, 70% of which was for GeneXpert cartridges. The estimated cost per person screened was $36 (95% uncertainty range [95% UR] 34–38), and the cost per person diagnosed with Xpert-positive TB was $8,400 (95% UR 8,000–8,900). The prevalence of TB in the underlying community was the primary modifiable determinant of the cost per person diagnosed.CONCLUSION: Door-to-door screening can be feasibly performed at scale, but will require effective triage and identification of high-prevalence populations to be affordable and cost-effective.

Published
2023
Full Text
View/download PDF

5. Understanding patient-level costs of weekly isoniazid-rifapentine (3HP) among people living with HIV in Uganda

Author

Sung, J., primary, Musinguzi, A., additional, Kadota, J. L., additional, Baik, Y., additional, Nabunje, J., additional, Welishe, F., additional, Bishop, O., additional, Berger, C. A., additional, Katahoire, A., additional, Nakitende, A., additional, Nakimuli, J., additional, Akello, L., additional, Kasidi, J. R., additional, Kunihira Tinka, L., additional, Kamya, M. R., additional, Sohn, H., additional, Kiwanuka, N., additional, Katamba, A., additional, Cattamanchi, A., additional, Dowdy, D. W., additional, and Semitala, F. C., additional

Published
2023
Full Text
View/download PDF

7. Considering equity in priority setting using transmission models:Recommendations and data needs

Author

Quaife, M., Medley, G. F., Jit, M., Drake, T., Asaria, M., van Baal, P., Baltussen, R., Bollinger, L., Bozzani, F., Brady, O., Broekhuizen, H., Chalkidou, K., Chi, Y. L., Dowdy, D. W., Griffin, S., Haghparast-Bidgoli, H., Hallett, T., Hauck, K., Hollingsworth, T. D., McQuaid, C. F., Menzies, N. A., Merritt, M. W., Mirelman, A., Morton, A., Ruiz, F. J., Siapka, M., Skordis, J., Tediosi, F., Walker, P., White, R. G., Winskill, P., Vassall, A., Gomez, G. B., Quaife, M., Medley, G. F., Jit, M., Drake, T., Asaria, M., van Baal, P., Baltussen, R., Bollinger, L., Bozzani, F., Brady, O., Broekhuizen, H., Chalkidou, K., Chi, Y. L., Dowdy, D. W., Griffin, S., Haghparast-Bidgoli, H., Hallett, T., Hauck, K., Hollingsworth, T. D., McQuaid, C. F., Menzies, N. A., Merritt, M. W., Mirelman, A., Morton, A., Ruiz, F. J., Siapka, M., Skordis, J., Tediosi, F., Walker, P., White, R. G., Winskill, P., Vassall, A., and Gomez, G. B.

Abstract

Objectives: Disease transmission models are used in impact assessment and economic evaluations of infectious disease prevention and treatment strategies, prominently so in the COVID-19 response. These models rarely consider dimensions of equity relating to the differential health burden between individuals and groups. We describe concepts and approaches which are useful when considering equity in the priority setting process, and outline the technical choices concerning model structure, outputs, and data requirements needed to use transmission models in analyses of health equity. Methods: We reviewed the literature on equity concepts and approaches to their application in economic evaluation and undertook a technical consultation on how equity can be incorporated in priority setting for infectious disease control. The technical consultation brought together health economists with an interest in equity-informative economic evaluation, ethicists specialising in public health, mathematical modellers from various disease backgrounds, and representatives of global health funding and technical assistance organisations, to formulate key areas of consensus and recommendations. Results: We provide a series of recommendations for applying the Reference Case for Economic Evaluation in Global Health to infectious disease interventions, comprising guidance on 1) the specification of equity concepts; 2) choice of evaluation framework; 3) model structure; and 4) data needs. We present available conceptual and analytical choices, for example how correlation between different equity- and disease-relevant strata should be considered dependent on available data, and outline how assumptions and data limitations can be reported transparently by noting key factors for consideration. Conclusions: Current developments in economic evaluations in global health provide a wide range of methodologies to incorporate equity into economic evaluations. Those employing infectious disease models n

Published
2022

14. Costs along the TB diagnostic pathway in Uganda

Author

Tucker, A., primary, Oyuku, D., additional, Nalugwa, T., additional, Nantale, M., additional, Ferguson, O., additional, Farr, K., additional, Reza, T. F., additional, Shete, P. B., additional, Cattamanchi, A., additional, Dowdy, D. W., additional, Sohn, H., additional, and Katamba, A., additional

Published
2021
Full Text
View/download PDF

29. Feasibility of a streamlined tuberculosis diagnosis and treatment initiation strategy

Author

Shete, P. B., primary, Nalugwa, T., additional, Farr, K., additional, Ojok, C., additional, Nantale, M., additional, Howlett, P., additional, Haguma, P., additional, Ochom, E., additional, Mugabe, F., additional, Joloba, M., additional, Chaisson, L. H., additional, Dowdy, D. W., additional, Moore, D., additional, Davis, J. L., additional, Katamba, A., additional, and Cattamanchi, A., additional

Published
2017
Full Text
View/download PDF

31. Lower Pill Burden and Once-Daily Antiretroviral Treatment Regimens for HIV Infection: A Meta-Analysis of Randomized Controlled Trials

Author

Nachega, J. B., Parienti, J.-J., Uthman, Olalekan A., Gross, R., Dowdy, D. W., Sax, P. E., Gallant, J. E., Mugavero, M. J., Mills, E. J., and Giordano, T. P.

Subjects
wc_503_2, wc_503_6, wc_503
Abstract

Background\ud \ud Contemporary antiretroviral treatment regimens are simpler than in the past, with lower pill burden and once-daily dosing frequency common. We performed a meta-analysis of randomized controlled trials (RCTs) to investigate the impact of pill burden and once-daily vs twice-daily dosing on ART adherence and virological outcomes.\ud \ud Methods\ud \ud A literature search of 4 electronic databases through 31 March 2013 was used. RCTs comparing once-daily vs twice-daily ART regimens that also reported on adherence and virological suppression were included. Study design, study population characteristics, intervention, outcome measures, and study quality were extracted. Study quality was rated using the Cochrane risk-of-bias tool.\ud \ud Results\ud \ud Nineteen studies met our inclusion criteria (N = 6312 adult patients). Higher pill burden was associated with both lower adherence rates (P = .004) and worse virological suppression (P < .0001) in both once-daily and twice-daily subgroups, although the association with adherence in the once-daily subgroup was not statistically significant. The average adherence was modestly higher in once-daily regimens than twice-daily regimens (weighted mean difference = 2.55%; 95% confidence interval [CI], 1.23 to 3.87; P = .0002). Patients on once-daily regimens did not achieve virological suppression more frequently than patients on twice-daily regimens (relative risk [RR] = 1.01; 95% CI, 0.99 to 1.03; P = .50). Both adherence and viral load suppression decreased over time, but adherence decreased less with once-daily dosing than with twice-daily dosing.\ud \ud Conclusions\ud \ud Lower pill burden was associated with both better adherence and virological suppression. Adherence, but not virological suppression, was slightly better with once- vs twice-daily regimens.

Published
2014

32. Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis

Author

Gomez, G. B., primary, Dowdy, D. W., additional, Bastos, M. L., additional, Zwerling, A., additional, Sweeney, S., additional, Foster, N., additional, Trajman, A., additional, Islam, M. A., additional, Kapiga, S., additional, Sinanovic, E., additional, Knight, G. M., additional, White, R. G., additional, Wells, W. A., additional, Cobelens, F. G., additional, and Vassall, A., additional

Published
2016
Full Text
View/download PDF

34. Quality of life among people treated for tuberculosis and human immunodeficiency virus in Rio de Janeiro, Brazil

Author

Dowdy, D. W., Israel, G., Vellozo, V., Saraceni, V., Cohn, S., Cavalcante, S., Chaisson, R. E., Golub, J. E., and Durovni, B.

Subjects
Adult, Male, Analysis of Variance, Anti-HIV Agents, Coinfection, Health Status, Antitubercular Agents, Urban Health, virus diseases, HIV Infections, Article, Disability Evaluation, Cross-Sectional Studies, Mental Health, Treatment Outcome, Health Care Surveys, Surveys and Questionnaires, Linear Models, Quality of Life, Humans, Tuberculosis, Female, Brazil
Abstract

We measured quality of life (QOL) among individuals receiving treatment for human immunodeficiency virus (HIV; n = 45), active tuberculosis (TB; n = 44) and both TB and HIV (n = 9) in Rio de Janeiro, Brazil. Active treated TB was associated with lower physical health (absolute decrease of 0.95 standard deviation in summary score), but not mental health, among people being treated for HIV. Visual analogue scale scores were similar across all three populations, and corresponded closely to standard disability weights used in the literature. Among patients receiving treatment, those with HIV, active TB and both conditions together appear to have similar QOL.

Published
2013

49. Opportunities and Challenges for Cost-Efficient Implementation of New Point-of-Care Diagnostics for HIV and Tuberculosis

Author

Schito, M., primary, Peter, T. F., additional, Cavanaugh, S., additional, Piatek, A. S., additional, Young, G. J., additional, Alexander, H., additional, Coggin, W., additional, Domingo, G. J., additional, Ellenberger, D., additional, Ermantraut, E., additional, Jani, I. V., additional, Katamba, A., additional, Palamountain, K. M., additional, Essajee, S., additional, and Dowdy, D. W., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results